NIP
MIRM icon

Nicholas Investment Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Nicholas Investment Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.1M Sell
131,303
-82,088
-38% -$7.72M 0.88% 35
2025
Q4 		$16.9M Sell
213,391
-3,677
-2% -$264K 1.23% 11
2025
Q3 		$15.9M Buy
217,068
+32,585
+18% +$2.07M 1.22% 12
2025
Q2 		$9.39M Buy
184,483
+11,440
+7% +$509K 0.84% 29
2025
Q1 		$7.8M Buy
173,043
+24,200
+16% +$1.14M 0.8% 36
2024
Q4 		$6.15M Buy
148,843
+4,364
+3% +$182K 0.54% 65
2024
Q3 		$5.63M Buy
+144,479
New +$5.76M 0.52% 67
2024
Q2 		– Sell
-151,002
Closed -$3.79M – 227
2024
Q1 		$3.79M Sell
151,002
-247,881
-62% -$6.81M 0.39% 98
2023
Q4 		$11.8M Sell
398,883
-800,483
-67% -$24.2M 1.38% 14
2023
Q3 		$37.9M Buy
1,199,366
+284,247
+31% +$7.78M 2.83% 4
2023
Q2 		$23.7M Buy
+915,119
New +$24.3M 1.62% 18

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Nicholas Investment Partners's MIRM Position: Q1 2026 in Review

Nicholas Investment Partners reduced its Mirum Pharmaceuticals (MIRM) stake by 38% in Q1 2026, selling an estimated $7.72M and leaving 131,303 shares worth $12.1M. The position accounts for 0.88% of the portfolio, ranked #35.

Nicholas Investment Partners first reported a position in MIRM in Q2 2023 and has held it in 11 quarters since. The position peaked at $37.9M in Q3 2023. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Nicholas Investment Partners held 131,303 shares of Mirum Pharmaceuticals worth $12.1M as of Q1 2026.
  • Nicholas Investment Partners sold 82,088 Mirum Pharmaceuticals shares in Q1 2026, an estimated $7.72M.
  • Mirum Pharmaceuticals made up 0.88% of Nicholas Investment Partners's portfolio in Q1 2026, its #35 holding.
  • Nicholas Investment Partners first reported a position in Mirum Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • Nicholas Investment Partners's Mirum Pharmaceuticals position peaked at $37.9M in Q3 2023.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Nicholas Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.